Condition: Myelofibrosis · Primary Myelofibrosis · Post-PV MF · Sponsor: Telios Pharma, Inc.
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
This description comes directly from the study's public registry record.
John Mei · 650-542-0136 · jmei@teliospharma.com
Nikki Stuart · nzona@teliospharma.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Gabrail Cancer Center | Canton, Ohio, United States | Recruiting |
| University of Cincinnati (UC) | Cincinnati, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| AP-HM - Hôpital de la Timone | Marseille, France | Recruiting |
| CHU de Nice - Hopital L'Archet II | Nice, France | Recruiting |
| Hôpital Saint Louis - AP-HP | Paris, France | Recruiting |
| Centre Hospitalier Lyon Sud | Pierre-Bénite, France | Recruiting |
| Marien Hospital Duesseldorf | Düsseldorf, Germany | Recruiting |
| Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall | Halle, Germany | Recruiting |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola | Bologna, Italy | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05280509